91 related articles for article (PubMed ID: 36443430)
1.
Haidar M; Abi-Ghanem AS; Moukaddam H; Jebai ME; Al Zakleet S; Al Rayess S; Akkawi AR; Kassas M; Tamim H; Hajj AE; Estrada-Lobato E; Osman MM; Shamseddine A
Sci Rep; 2022 Nov; 12(1):20500. PubMed ID: 36443430
[TBL] [Abstract][Full Text] [Related]
2. Presurgical
Djaïleb L; Armstrong WR; Thompson D; Gafita A; Farolfi A; Rajagopal A; Grogan TR; Nguyen K; Benz MR; Hotta M; Barbato F; Ceci F; Schwarzenböck SM; Unterrainer M; Zacho HD; Juarez R; Cooperberg M; Carroll P; Washington S; Reiter RE; Eiber M; Herrmann K; Fendler WP; Czernin J; Hope TA; Calais J
Eur Urol; 2023 Dec; 84(6):588-596. PubMed ID: 37482512
[TBL] [Abstract][Full Text] [Related]
3. The management impact of
Kulkarni M; Hughes S; Mallia A; Gibson V; Young J; Aggarwal A; Morris S; Challacombe B; Popert R; Brown C; Cathcart P; Dasgupta P; Warbey VS; Cook GJR
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):674-686. PubMed ID: 31872280
[TBL] [Abstract][Full Text] [Related]
4. A Phase II, Open-label study to assess safety and management change using
Afaq A; Payne H; Davda R; Hines J; Cook GJR; Meagher M; Priftakis D; Warbey VS; Kelkar A; Orczyk C; Mitra A; Needleman S; Ferris M; Mullen G; Bomanji J
J Nucl Med; 2021 Mar; 62(12):1727-34. PubMed ID: 33741648
[No Abstract] [Full Text] [Related]
5. Flare on [
Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
[TBL] [Abstract][Full Text] [Related]
6.
Xu L; Chen R; Yu X; Liu J; Wang Y
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201316
[TBL] [Abstract][Full Text] [Related]
7. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [
Onal C; Guler OC; Torun N; Oymak E; Reyhan M
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3755-3764. PubMed ID: 37402832
[TBL] [Abstract][Full Text] [Related]
8. The superior detection rate of total-body [
Wang Y; Dong L; Zhao H; Li L; Huang G; Xue W; Liu J; Chen R
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38514483
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
[TBL] [Abstract][Full Text] [Related]
10. Current status of theranostics in prostate cancer.
Virgolini I; Decristoforo C; Haug A; Fanti S; Uprimny C
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):471-495. PubMed ID: 29282518
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Digital versus Analog
Rovera G; Grimaldi S; Dall'Armellina S; Zotta M; Finessi M; Passera R; Deandreis D
Diagnostics (Basel); 2023 Nov; 13(23):. PubMed ID: 38066776
[TBL] [Abstract][Full Text] [Related]
12. [
Werner P; Neumann C; Eiber M; Wester HJ; Schottelius M
EJNMMI Res; 2020 May; 10(1):45. PubMed ID: 32382945
[TBL] [Abstract][Full Text] [Related]
13. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence.
Li Y; Wang S; Zhao S; Zhao P; Huang S; Li K; Han S; Tian C; Li X; Shi B; Li X
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38563882
[TBL] [Abstract][Full Text] [Related]
14. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy.
Payne H; Bomanji J; Bottomley D; Scarsbrook AF; Teoh EJ;
Nucl Med Commun; 2022 Feb; 43(2):201-211. PubMed ID: 34669678
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of machine learning strategies for imaging confirmed prostate cancer recurrence prediction on electronic health records.
Beinecke JM; Anders P; Schurrat T; Heider D; Luster M; Librizzi D; Hauschild AC
Comput Biol Med; 2022 Apr; 143():105263. PubMed ID: 35131608
[TBL] [Abstract][Full Text] [Related]
16. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.
Murthy V; Appiah-Kubi E; Nguyen K; Thin P; Hotta M; Shen J; Drakaki A; Rettig M; Gafita A; Calais J; Sonni I
Eur J Hybrid Imaging; 2023 Oct; 7(1):18. PubMed ID: 37779132
[TBL] [Abstract][Full Text] [Related]
17. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.
Falkenbach F; Ambrosini F; Tennstedt P; Eiber M; Heck MM; Preisser F; Graefen M; Budäus L; Koehler D; Knipper S; Maurer T
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894375
[TBL] [Abstract][Full Text] [Related]
18. Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
Einstein DJ; Aragon-Ching JB; Karzai F; Madan RA
Curr Opin Oncol; 2024 May; 36(3):164-168. PubMed ID: 38573205
[TBL] [Abstract][Full Text] [Related]
19. Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?
Laudicella R; Bauckneht M; Maurer A; Heimer J; Gennari AG; Di Raimondo T; Paone G; Cuzzocrea M; Messerli M; Eberli D; Burger IA
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001731
[TBL] [Abstract][Full Text] [Related]
20. Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.
Gotto GT; Yu C; Bernstein M; Eastham JA; Kattan MW
Front Oncol; 2014; 4():296. PubMed ID: 25386410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
